Core Viewpoint - Shenzhen Guangdao Digital Technology Co., Ltd. faces a significant risk of being forcibly delisted due to major legal violations, as indicated by the China Securities Regulatory Commission's investigation and subsequent notifications [2][3][6] Group 1: Investigation and Delisting Risk - The company was investigated by the China Securities Regulatory Commission on December 4, 2024, for suspected violations of information disclosure [3] - On June 13, 2025, the company received a notice indicating that it may be subject to forced delisting due to major legal violations as per the Beijing Stock Exchange listing rules [2][3] - The company has issued multiple risk warning announcements regarding the potential for forced delisting, with the first warning issued on June 13, 2025, and subsequent warnings issued regularly [3][4][6] Group 2: Regulatory Compliance and Future Actions - The company has not planned any major restructuring, debt restructuring, or significant business collaborations, urging investors to be cautious of stock price speculation risks [3][6] - The company is committed to cooperating fully with the regulatory authorities and will adhere to information disclosure obligations as required [6] - If a formal administrative penalty decision is received, the company will apply for a trading suspension and disclose relevant information promptly [6]

公司于 2025 年 2 月 26 日收到中国证监会《立案告知书》（证监立案字 法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公司立案。 具体内容详见公司于 2025 年 2 月 27 日披露的《关于收到中国证券监督管理委员 会立案告知书暨风险提示公告》（公告编号：临 2025-007）。 （处 证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-102 江苏吴中医药发展股份有限公司关于公司股票 可能被实施重大违法强制退市的第九次风险提示公告 正式处罚决定为准。敬请广大投资者关注后续公告并注意投资风险。 司后续收到行政处罚决定书，显示公司触及重大违法类强制退市情形，公司将申 请停牌，并及时披露有关内容。上海证券交易所将在停牌之日起的 5 个交易日内， 向公司发出拟终止股票上市的事先告知书，后续将根据《上海证券交易所股票上 市规则》的相关规定，作出是否终止公司股票上市的决定。 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要风险提示： 罚字〔2025〕58 号），认定公司子公司江苏吴中进出口有限公 ...

Core Viewpoint - The company, Yuancheng Environment Co., Ltd., is under investigation by the China Securities Regulatory Commission (CSRC) for suspected false disclosures in financial reports, which poses significant risks of forced delisting due to major violations [1][3]. Financial Risks - For the first half of 2025, the company reported revenue of 82.34 million yuan and a net loss attributable to shareholders of 126.80 million yuan, which may lead to delisting risks if the annual report does not meet the requirements set by the Shanghai Stock Exchange [2]. - The company is subject to a risk warning due to its financial performance, and if the 2025 annual report does not meet the delisting criteria, the company's stock may be terminated from listing [2]. Operational Status - As of the announcement date, the company's business activities are reported to be operating normally, and the CSRC's investigation is ongoing without any conclusive findings yet [3]. - The company and its controlling shareholder are cooperating with the CSRC's investigation and will provide monthly updates on the progress of the investigation as required by the stock listing rules [3]. Risk Warnings - The company faces uncertainties regarding its ability to continue operations and liquidity risks, with multiple bank accounts frozen, totaling a significant amount in restricted funds [2].

Core Viewpoint - *ST Suwu has issued multiple warnings regarding significant trading risks and potential forced delisting due to abnormal stock price fluctuations and regulatory issues [1][3][7]. Group 1: Trading Risks - On August 27, *ST Suwu announced that its stock price had deviated significantly, with a cumulative increase of over 12% in two consecutive trading days, indicating abnormal trading activity [4]. - The stock experienced a substantial increase over five consecutive trading days, with a trading turnover rate of 20.93% on August 27, suggesting a "hot potato" trading phenomenon [4]. - The company has warned that if further significant trading anomalies occur, it will apply for a trading suspension to protect the rights of small investors [4]. Group 2: Regulatory Issues - *ST Suwu received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) on July 13, indicating that the company had inflated its operating income, costs, and profits, leading to false records in annual reports from 2020 to 2023 [7]. - The company is at risk of being subjected to forced delisting due to these violations of the Shanghai Stock Exchange listing rules [7][9]. - As of July 14, *ST Suwu's stock has been under a delisting risk warning, and if the CSRC's final decision confirms the violations, the stock will be terminated from listing [9]. Group 3: Financial and Operational Status - The company conducted a self-examination and found no significant changes in its daily operations or external environment that would impact its stock price, nor any undisclosed major events [6]. - The controlling shareholder's related parties have non-operating fund occupation amounting to 1.693 billion yuan as of the end of 2023 [9]. - The company is currently facing operational challenges due to a contract termination with Regen Biotech Inc., affecting its ability to sell AestheFill products [9].

Core Viewpoint - *ST Suwu has issued a warning regarding significant trading risks and potential forced delisting due to multiple ongoing issues, including financial fraud and substantial losses in its operations [1][2][5]. Group 1: Trading Risks - The company has experienced a significant stock price increase recently, which has raised concerns about trading risks, described as "obvious signs of a hot potato" [1][5]. - Since being investigated, *ST Suwu has issued over 40 warnings about the risk of forced delisting due to major violations [5]. Group 2: Financial Misconduct - The company has been found guilty of financial fraud over several years, which has led to the issuance of an administrative penalty notice by the China Securities Regulatory Commission [2][4]. - The company is at risk of being delisted as it has violated the Shanghai Stock Exchange's regulations regarding major misconduct [2]. Group 3: Performance Decline - *ST Suwu has projected a significant loss for the first half of 2025, estimating a net profit loss of approximately 60 million to 40 million yuan [3]. - The company's medical aesthetics business has faced severe setbacks, including the termination of exclusive distribution rights for a key product, AestheFill, leading to halted sales [3]. Group 4: Financial Health - The company reported a non-operating fund occupation of 769 million yuan, which has escalated to 1.693 billion yuan, representing 96.09% of its net assets [4]. - The controlling shareholder's shares are currently frozen, indicating potential financial instability and lack of resolution for the fund occupation issue [4].

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. faces significant risks of stock trading anomalies and potential forced delisting due to violations of financial reporting standards and substantial fund occupation by its controlling shareholder [1][2][3] Stock Trading Anomalies - The company's stock price has deviated significantly, with a cumulative increase of over 12% in closing prices over two consecutive trading days (August 26 and 27, 2025) [2] - On August 27, 2025, the trading turnover rate reached 20.93%, indicating a high level of speculative trading activity [1] Company Operations and Financial Status - As of the announcement date, the company reported no significant changes in its daily operations or external environment beyond previously disclosed matters [2] - The company confirmed that there are no undisclosed major events, such as asset restructuring or significant business partnerships, that could impact its stock price [2][3] Regulatory and Legal Issues - The company received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) on July 13, 2025, for inflating revenue, costs, and profits in its annual reports from 2020 to 2023, which may lead to forced delisting [1][3] - The company has been under a delisting risk warning since July 14, 2025, due to the aforementioned violations [3] Financial Risks - The controlling shareholder's related parties have a non-operating fund occupation balance of 1.6926071 billion yuan as of the end of 2023, which poses additional financial risks [4] - The company is facing multiple delisting risks, including financial delisting and violations of major laws [2][4] Business Disruptions - The company has faced disruptions in its medical aesthetics business due to the termination of exclusive agency agreements, which has halted related operations [4] - The company is currently unable to continue selling certain products due to legal disputes arising from contract breaches [4] Board Statements - The board of directors confirmed that there are no undisclosed matters that should be reported according to the Shanghai Stock Exchange listing rules [4][5]

Core Points - The company, Beijing Oriental Tong Technology Co., Ltd., has been investigated by the China Securities Regulatory Commission (CSRC) for suspected false disclosures in its periodic reports [4][5][6] - The independent directors expressed their inability to verify the accuracy and completeness of the financial data in the 2025 semi-annual report due to the ongoing investigation [2][3] - The company reported a significant increase in operating revenue by 48.85% year-on-year, amounting to approximately 239.93 million yuan, while the net profit attributable to shareholders improved by 66.80%, reaching a loss of about 55.16 million yuan [5] Financial Performance - Operating revenue for the reporting period was 239,929,168.10 yuan, compared to 161,184,732.53 yuan in the same period last year, reflecting a growth of 48.85% [5] - The net profit attributable to shareholders was -55,158,035.97 yuan, an improvement from -166,134,971.77 yuan, indicating a 66.80% reduction in losses [5] - The net cash flow from operating activities was 22,949,517.56 yuan, a significant turnaround from -178,984,131.50 yuan, marking a 112.82% increase [5] Shareholder Information - The company does not plan to distribute cash dividends or issue bonus shares, nor will it increase capital from reserves [3] - The top shareholder, Huang Yongjun, holds 7.35% of the shares, with a portion of his shares pledged [5][6] - The company has not experienced any changes in its controlling shareholder or actual controller during the reporting period [6]

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. faces significant risks of forced delisting due to major violations and financial issues, including false reporting of revenue and profits from 2020 to 2023 [4]. Group 1: Major Violation Delisting Risk - The company received an administrative penalty notice from the China Securities Regulatory Commission (CSRC) for falsely inflating operating income, costs, and profits, which may lead to forced delisting [4]. - The company’s stock has been under risk warning since July 14, 2025, due to the potential for major violations leading to termination of listing [1][4]. Group 2: Financial Delisting Risk - The 2024 financial report received a disclaimer of opinion from the auditing firm, triggering financial delisting risks under the Shanghai Stock Exchange rules [1][2]. - The company is currently under risk warning due to financial issues, including the inability to express an opinion on internal controls [2]. Group 3: Other Risk Warnings - The company is facing additional risk warnings due to non-operational fund occupation by related parties, which violates stock exchange regulations [2]. - The company has also encountered operational risks, including a contract termination with a medical product distributor, affecting sales [2]. Group 4: Investor Advisory - The company urges investors to be cautious and rational in their investment decisions, especially given the recent abnormal stock price fluctuations that do not align with deteriorating fundamentals [4].

Group 1 - The company experienced significant stock price fluctuations, with a cumulative decline exceeding 12% over two consecutive trading days and over 70% in 27 trading days, indicating severe abnormal trading conditions [1][4][5] - The company received a notice from the China Securities Regulatory Commission regarding potential administrative penalties for fraudulent issuance of shares and false records in annual reports from 2015 to 2023, which may lead to delisting [1][5][6] - The company has been under risk warning since August 11, 2025, due to the aforementioned issues, and is subject to further regulatory scrutiny [1][6] Group 2 - The company is involved in multiple lawsuits, with 9 cases previously filed and 12 additional cases related to similar matters, indicating ongoing legal challenges [2][3] - As of February 12, 2025, the company had a total of approximately 140 million yuan executed against its bank accounts, with a remaining balance of about 16.7 million yuan yet to be executed [2][3] - The company has faced adverse court rulings, including the rejection of jurisdictional objections, which may impact its legal standing and financial situation [2][3]

Core Viewpoint - Fujian Securities Regulatory Commission imposed a total fine of 384 million yuan on *ST Zitian for illegal information disclosure and failure to disclose the 2024 annual report within the statutory deadline [1][2] Group 1: Financial Misconduct - *ST Zitian inflated revenue by 2.499 billion yuan over two consecutive years, with three financial reports containing fraudulent activities [1] - In the 2022 annual report, *ST Zitian falsely reported internet advertising fees and SMS services, resulting in an inflated revenue of 778 million yuan and inflated profit of 85 million yuan, accounting for 44.59% and 35.99% of total revenue and profit respectively [1] - The 2023 semi-annual report showed an inflated revenue of 208 million yuan and profit of 79 million yuan due to premature revenue recognition in cloud services, representing 14.56% and 51.64% of total revenue and profit respectively [1] Group 2: Penalties and Legal Actions - The total penalty of 384 million yuan includes 277 million yuan for the company and 12 management personnel, with lifetime bans imposed on the former chairman and the CFO [2] - An additional fine of 3.5 million yuan was levied for failing to disclose the 2024 annual report on time, along with 3.4 million yuan for management personnel [2] - The company received a notice from the Shenzhen Stock Exchange regarding the potential termination of its stock listing due to financial fraud, which may lead to a forced delisting risk [2] Group 3: Criminal Investigation - The public security authorities initiated a criminal case against *ST Zitian for concealing accounting vouchers, which meets the standards for prosecution for "illegal disclosure and non-disclosure of important information" [3] - Investors have already filed civil compensation lawsuits against the company [3]